BlackBarn Capital Partners LP Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

BlackBarn Capital Partners LP raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 63.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,100,000 shares of the company’s stock after purchasing an additional 1,199,406 shares during the quarter. Roivant Sciences accounts for approximately 2.9% of BlackBarn Capital Partners LP’s portfolio, making the stock its largest position. BlackBarn Capital Partners LP owned about 0.42% of Roivant Sciences worth $32,767,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. nVerses Capital LLC bought a new position in shares of Roivant Sciences in the second quarter valued at approximately $34,000. Acadian Asset Management LLC purchased a new position in Roivant Sciences during the 1st quarter worth $72,000. Fifth Third Wealth Advisors LLC bought a new stake in shares of Roivant Sciences in the 2nd quarter worth $101,000. ORG Partners LLC purchased a new stake in shares of Roivant Sciences in the second quarter valued at about $106,000. Finally, Capstone Investment Advisors LLC bought a new position in shares of Roivant Sciences during the fourth quarter valued at about $170,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler boosted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.39.

Roivant Sciences Trading Down 1.8 %

Shares of Roivant Sciences stock opened at $11.69 on Wednesday. The stock has a market capitalization of $8.64 billion, a P/E ratio of 2.31 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $8.24 and a 52-week high of $13.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The stock’s 50-day simple moving average is $11.47 and its 200 day simple moving average is $11.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same period in the prior year, the company posted ($0.38) EPS. Roivant Sciences’s revenue was up 155.1% compared to the same quarter last year. As a group, research analysts anticipate that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

Insider Transactions at Roivant Sciences

In related news, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Matthew Gline sold 1,983,257 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the transaction, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. The disclosure for this sale can be found here. Corporate insiders own 4.60% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.